1. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Issue 3 (March 2023) Authors: Laffel, Lori M; Danne, Thomas; Klingensmith, Georgeanna J; Tamborlane, William V; Willi, Steven; Zeitler, Philip; Neubacher, Dietmar; Marquard, Jan; Bardymova, Tatiana; Barrientos Perez, Margarita; Bethin, Kathleen; Bjornstad, Petter; Bondar, Irina; Chen, Mimi; Choi, Jin-Ho; Clements, Mark A; Col... Journal: Lancet Issue: Volume 11:Issue 3(2023) Page Start: 169 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. Issue 2 (February 2022) Authors: Fleseriu, Maria; Dreval, Alexander; Bondar, Irina; Vagapova, Gulnar; Macut, Djuro; Pokramovich, Yulia G; Molitch, Mark E; Leonova, Nina; Raverot, Gerald; Grineva, Elena; Poteshkin, Yury E; Gilgun-Sherki, Yossi; Ludlam, William H; Patou, Gary; Haviv, Asi; Gordon, Murray B; Biermasz, Nienke R; Melm... Journal: Lancet Issue: Volume 10:Issue 2(2022) Page Start: 102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗